Barclays lowered the firm’s price target on Intellia Therapeutics (NTLA) to $55 from $76 and keeps an Overweight rating on the shares following the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Reports Q3 2024 Financial Progress
- Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch
- Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39)
- Intellia Therapeutics Inc (NTLA) Q3 Earnings Cheat Sheet
- Intellia Therapeutics Advances with Promising Phase 2 Results